MDS in ASH 2021 – Are we already in the molecular era? [MDS Professional Report]
Feb 6, 2022 ·
36m 11s
![MDS in ASH 2021 – Are we already in the molecular era? [MDS Professional Report]](https://d3wo5wojvuv7l.cloudfront.net/t_square_limited_480/images.spreaker.com/original/6f4d6f2e2159220a3406f67f0e6f82f9.jpg)
Download and listen anywhere
Download your favorite episodes and enjoy them, wherever you are! Sign up or log in now to access offline listening.
Description
Drs. Moshe Mittelman, of The Tel Aviv Sourasky Medical Center, and Drorit Merkel, of the Sheba Medical Center, both from Tel Aviv University, Israel, discuss several important presentations from the...
show more
Drs. Moshe Mittelman, of The Tel Aviv Sourasky Medical Center, and Drorit
Merkel, of the Sheba Medical Center, both from Tel Aviv University, Israel,
discuss several important presentations from the recent 2021 ASH meeting.
They focus on the new IPSS-M classification, discuss the approach to the
MDS patient who is currently defined by IPSS/R as belonging to the /lower-
risk group but in fact the disease behaves like a higher-risk. Finally, they
discuss issues regarding the treatment of patients with HR-MDS: What can be
added to hypomethylating agents ? Targeted therapy with IDH1/2 inhibition
and more…
show less
Merkel, of the Sheba Medical Center, both from Tel Aviv University, Israel,
discuss several important presentations from the recent 2021 ASH meeting.
They focus on the new IPSS-M classification, discuss the approach to the
MDS patient who is currently defined by IPSS/R as belonging to the /lower-
risk group but in fact the disease behaves like a higher-risk. Finally, they
discuss issues regarding the treatment of patients with HR-MDS: What can be
added to hypomethylating agents ? Targeted therapy with IDH1/2 inhibition
and more…
Information
| Author | PI Media |
| Organization | PodIl |
| Website | - |
| Tags |
-
|
Copyright 2024 - Spreaker Inc. an iHeartMedia Company
Comments